About WntResearch

“WntResearch is developing an entirely new kind of cancer drug, which inhibits the tumour cells’ ability to spread through the body and metastasize.”  

Peter Morsing, CEO

Mestastasis-inhibiting drugs are badly needed.  

One in every three people in Sweden will contract cancer during their lifetimes. Although modern cancer therapies have become efficient at fighting tumours and saving lives, effective treatment against metastasis – the spread of tumour cells to other organs in the body – is still not available. Metastasis in solid tumours is regarded as the cause of approximately 90 percent of all cancer-related deaths.  

The lack of drugs that inhibit metastasis is the driving force behind WntResearch – along with the urge to capitalize on the properties of WNT5A with Foxy-5/Box-5. The therapies available on the market today are expensive, and focus mainly on patients with recurring tumours. These therapies also have undesirable side effects. With the drug candidate Foxy-5, WntResearch tries to prevent these secondary tumours from forming in the first place. The Board of Directors believes that this approach to cancer treatment is unique to WntResearch.

During 2018, WntResearch has successfully optimized the design of a phase 2 study with Foxy-5; the initiation of the study brings the Company to the market as a phase 2 company. The phase 2 study is estimated to be able to generate indicative results already in Q2 2020, and the study’s open design makes it possible to gather and evaluate treatment results continuously. The objective of the study is to demonstrate that Foxy-5 has an effect on metastasis and relapse risk in patients with colon cancer.

A positive indication of effect would mean a significant milestone for the company within the colon cancer indication, and would also provide the basis for further development of Foxy-5 in other indications such as breast and prostate cancer. Such indications would also provide WntResearch with a stronger platform for discussing cooperations with pharmaceutical companies, both for further development within the colon cancer indication and in other cancer indications. The company also recognizes the opportunity to seek additional strategic financing and perform clinical trials within these indications on its own.